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Abstract
Background/Aims: Viral infections represent a global health problem with the need for new 
viral therapies and better understanding of the immune response during infection. The most 
immediate and potent anti-viral defense mechanism is the production of type I interferon 
(IFN-I) which are activated rapidly following recognition of viral infection by host pathogen 
recognition receptors (PRR). The mechanisms of innate cellular signaling downstream of PRR 
activation remain to be fully understood. In the present study, we demonstrate that CASP2 and 
RIPK1 domain-containing adaptor with death domain (CRADD/RAIDD) is a critical component 
in type I IFN production. Methods: The role of RAIDD during IFN-I production was investigated 
using western blot, shRNA mediated lentiviral knockdown, immunoprecipitation and IFN-I 
driven dual luciferase assay. Results: Immunoprecipitation analysis revealed the molecular 
interaction of RAIDD with interferon regulatory factor 7 (IRF7) and its phosphorylating kinase 
IKKε. Using an IFN-4α driven dual luciferase analysis in RAIDD deficient cells, type I IFN 
activation by IKKε and IRF7 was dramatically reduced. Furthermore, deletion of either the 
caspase recruitment domain (CARD) or death domain (DD) of RAIDD inhibited IKKε and IRF7 
mediated interferon-4α activation. Conclusion: We have identified that the adaptor molecule 
RAIDD coordinates IKKε and IRF7 interaction to ensure efficient expression of type I interferon.
S.K. Maney and H.C. Xu contributed equally to this work and thus share first authorship; K.S. Lang and 
P.A. Lang contributed equally to this work and thus share last authorship.
© 2016 The Author(s)
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IntroductionInnate immune activation is critical in inducing anti-viral immunity through cytokine production and adaptive immune priming [1]. Antigen presenting cells including dendritic cells (DCs) recognize pathogens through pathogen recognition receptors (PRRs) [1]. Speci-
fically, DCs sense viral nucleic acids via PRRs including membrane bound toll like receptors 
TLRs, which results in production of type I interferon (IFN-I) and pro-inflammatory cytoki-
nes [1]. TLR9 senses DNA such as CpG oligoribonucleotides [2], while TLR7 recognizes sing-
le stranded RNA (mimicked by imiquimod) [3, 4] and TLR3 recognizes double stranded RNA 
(mimicked by PolyI:C) [5]. Following ligand binding, the intracellular domains of TLR7 and 
TLR9 bind a multi-protein complex composed of MyD88, TRAF6 [6], and the IL1-receptor 
interacting kinase (IRAK) family members IRAK4 and IRAK1, which can also be activated by 
other membrane proteins such as TREML4 [7, 8]. The activated complex triggers activation 
of IKKε, TBK1, IKKα and/or IRAK1. The later of which phosphorylate the transcription factor 
interferon regulatory factor 7 (IRF7) [9-11]. In contrast to TLR7 and TLR9, TLR3 signals via 
the adaptor molecule TRIF [12]. TRAF3 interacts with TRIF and is critical for the activation 
of downstream kinases IKKε and TBK1 [13, 14]. Coordinated activation of TLRs results in the 
phosphorylation of the transcription factors IRF7 and IRF3 [15-17]. Consequently, phospho-
rylated IRF7 and IRF3 then translocate into the nucleus followed by specific gene promoter 
binding to induce IFN-I gene transcription[18-20].
The death domain superfamily proteins are involved in various intracellular signaling 
cascades to orchestrate the innate and adaptive response against infection[21] (Table 1). In 
this study we have characterized one of the death domain superfamily proteins, the RIP as-
sociated ICH-1/CED-3-homologous protein with a death domain (RAIDD) carrying two func-
tional domains, a death domain (DD), as well as a caspase activation and recruitment domain 
(CARD) [22]. RAIDD is known to interact with RIP1 and is capable of inducing apoptosis 
[23]. Specifically, RAIDD plays a role in PIDD and heat shock induced apoptosis by recruiting 
caspase-2 [24, 25], although caspase-2 can also be activated independently of both PIDD 
and RAIDD [26]. Additionally, recent findings suggest that RAIDD suppresses inflammatory 
signaling mediated by NF-κB signaling in T cells by sequestering BCL10 [27]. However, the 
involvement of RAIDD during PRR signaling and its consequent innate immune response has 
not been described.
In this study we found that TLR3 driven IFN-I activation is inhibited in RAIDD defi-
cient cells. Mechanistically, RAIDD interacted with IRF7 and its phosphorylating kinase IKKε, 
thereby stimulating IKKε mediated IRF7 phosphorylation and promoting IFN-I production. 
Overall, these studies identify a novel adaptor molecule RAIDD, with an essential role in 
TLR3 driven IFN-I production.
Materials and Methods
Cell culture, Cloning, Plasmid preparation and Transfection
Human RAIDD was amplified using 5‘-TGC GGC CGC GGA GGC CAG AGA CAA ACA AGT-3‘and 5‘-TGT 
CGA CGA GGC ACC ATC ACT CCA ACA-3‘. Similarly, human RAIDD CARD domain with 279 bp in length was 
deleted (ΔC) using 5’-TAG CGG CCG CGA CCG ACC TGC CTG CAG GT-3’ and 5‘-TAG AGT CGA CGA GGC ACC 
ATC ACT-3’. The 249bp of human RAIDD DD domain were deleted (ΔD) using 5’-ATG ACA AGC TTG CGG 
CCG CGG A-3’ and 5‘-AGA GTC GAC TCA TGA TGG GGA GCT GTT GA-3‘.  Amplified products were initially 
cloned into the pGEM-T-easy cloning vector, thereafter subcloned into the p3XFlag-CMV-7.1 vector using 
NotI and SalI restriction enzymes. Human IKKε was amplified using 5’-AAG CTG GCT AGC GTA TGC AGA GCA 
CAG CCA ATT A-3’ and 5’- GAG ACT AGG GTC AGC GAC ATC AGG AGG TGC TGG-3’ and cloned into pGEM-T-
easy cloning vector, thereafter subcloned into pcDNA3.1/zeo with C-terminal HA-tag using NheI and PshAI restriction enzymes. Murine nucleotide sequence encoding RAIDD-C-term-HA was custom-synthesized by 
Gene script and cloned into pcDNA3.1/zeo (based on full ORF of NM_009950.2 with codon optimization for 
mouse expression). pBEN2-eYFP-IRF7A was obtained from CK. pUNO1-hΙΚΚε was purchased from Invivo-
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gen (puno1-hikkε). All the expression plasmids were amplified using promega maxi pre kit according to the 
manufactures instructions. Expression plasmids were transfected using lipofectamine 2000 or lipofecta-
mine LTX (Invitrogen) in 293t cells or HEK TLR3 cell lines. 24 h post transfection, cells were processed for 
further analysis. Unless otherwise indicated, cells were cultured in DMEM containing 10% FCS, L-Glutami-
ne, Penicillin, and Streptomycin.
Stable Knockdown of RAIDD
Lentiviral particles were generated by calcium phosphate transfection of sub-confluent (50-60%) 
293TV cells with 10μg of shRNA (Origene), 5 μg each of pMDG1.vsvg, pRSV-Rev and pMDLg/pRRE const-
ructs. Lentiviral particles were collected 24 and 48 hours later, filtered through a 0.45 μm filter and stored 
at -80°C. Parental cells (293t cells or HEK TLR3 cells) were infected with lentiviral particles containing the 
indicated shRNAs and cells were selected with puromycin (48 h, 5 μg/ml of puromycin). Two different spe-
cific RAIDD shRNA’s were used in the experiments.
IFN promoter assay
IFNβ promoter assay [28] and IFN4α promoter assays were performed as previously described [29]. 
Briefly, IFN luciferase promoter and reporters were used in the ratio of 10:1 and with plasmid alone or 
together with a combination of expression vectors at indicated concentration. The 293t cell lines or HEK 
TLR3 cell lines (Invivogen), reporter gene activities were measured by dual luciferase reporter assay system 
(Promega) after 24 h Post-transfection.
Immmunoblotting and Immunoprecipitation
Briefly, cells were lysed in PBS containing 1% TX-100 (Sigma), EDTA-free protease inhibitor cock-
tail (Sigma), Phospho stop (1 tablet/10 mL). Immunoblots were probed with primary anti-RAIDD (abcam 
ab8426), anti-IRF7 (Cell Signaling 4920 or 13014), and β-actin (Cell Signaling 5125). The pull-down was 
performed using MultiMACS HA/ GFP Isolation Kit or mAbs recognizing the FLAG.
Statistical analyses
Data are expressed as mean ± S.E.M. Statistical significant differences between two different groups 
were analyzed using students t test. Statistical differences between several groups were tested using one-
way ANOVA with additional Bonferroni or Dunnett’s post-tests. Statistically significant differences between 
groups in experiments involving more than one analysis time point were calculated using two-way ANOVA (repeated measurements).
Results
RAIDD is critical for IFN-I production after TLR3 stimulation
IFN-I is induced by activation of PRRs including Toll like receptors (TLRs) [30]. Particu-
larly, TLR3 can induce production of IFN-I following stimulation with its agonist PolyI:C [5]. 
To analyze the impact of RAIDD during TLR3 mediated IFN-I production, we generated HEK 
TLR3 transgenic cells, which stably express scramble (scrRNA) or shRNA against RAIDD (Fig. 
1A). When we challenged these cells with Poly I:C, they showed uniform expression of RAIDD 
at various time points (Fig. 1A). In order to investigate the presence or absence of TLR3 medi-
Table 1. Impact of Death Domain su-
perfamily proteins on signaling cascades. 
The death domain superfamily proteins 
described to be involved in various intra-
cellular signaling cascades (adopted from 
Park et al. [21])
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ated IFN-Ι activation signals, we used IFN4α 
promoter driven luciferase. When compared 
to untreated cells, Poly I:C treatment showed 
IFN-I activation evident by the expression of 
luciferase. However, cells lacking RAIDD ex-
pression showed significantly reduced acti-
vation of IFN-I after Poly I:C treatment (Fig. 
1B). Next, we examined the Poly I:C driven 
nuclear translocation of IRF7, which is one 
molecular hallmark during IFN-I activation 
[19, 31, 32]. RAIDD deficient cells showed 
impaired expression and nuclear transloca-
tion of IRF7, when compared to scramble 
control cells (Fig. 1C). Next, we checked the 
impact of RAIDD on other dsRNA sentinel 
receptors such as (MDA5) [33] and its potent 
Fig. 1. RAIDD is critical for IFN-I 
production after TLR3 agonist treat-
ment. (A) Whole cell lysates were pre-
pared from HEK TLR3 cells expressing 
scrRNA and shRNA RAIDD at indica-
ted time points and probed for RAIDD 
and β actin. (One representative of n = 
3 is shown) (B) HEK TLR3 cell lines, 
stably transduced with scramble or 
RAIDD-targeting shRNA, were trans-
fected with IFN4α luciferase promoter 
and Renilla constructs (10:1), and IF-
N4α promoter activity was measured 
after 6h of PolyI:C (25 µg/ml) treat-
ment. Luciferase activity as normali-
zed to Renilla luciferase activity was 
shown (n = 6 is shown) (C) HEK TLR3 
cytosolic and nuclear fractions were 
isolated at indicated time points and 
probed for IRF7, HISTONE H3, and 
GAPDH (one representative of n = 3 
is shown).
Fig. 2. RAIDD does not affect the RLR ligand MDA5 
or its adaptor IPS1 induced IFN-I activation. (A, B) IF-
N4α promoter luciferase activities were measured af-
ter transient transfection of indicated concentration of 
IPS1 (n = 6 is shown) and MDA5 (n = 6 is shown) (24 h 
post-transfection) from 293t cells stably expressing the 
scramble and shRNA of RAIDD.
adaptor molecule (IPS1) [34]; no notable difference in the activation of IFN-I was observed, 
either in presence or absence of RAIDD expression (Fig. 2A and B). Taken together, these 
data suggest that RAIDD specifically affects the TLR 3 mediated IFN-I activation.
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RAIDD triggers IRF7 mediated IFN-I transcription
Next, we investigated whether RAIDD may interact with IFN-I transcription factors. 
Co-immunoprecipitated RAIDD-HA showed interaction with endogenous IRF7; however, 
no interaction with the closely related IRF3 could be detected (Fig. 3A). These results were 
validated by reciprocal co-immunoprecipitation using IRF7-YFP to pull down endogenous 
RAIDD from the precipitated lysates (Fig. 3B). This interaction could be enriched when 
both molecules were co-expressed (Fig. 3A and B). Further, RAIDD-HA did not interact with 
TRAF6 (Fig. 3A) but in sharp contrast to enriched IRF7, which showed interaction as expec-
ted (Fig. 3B). The immunoprecipitation of RAIDD-HA or IRF7-YFP showed no sign of inter-
action with ΙκBα (Fig. 3A and B).  These results indicate that RAIDD affects IFN-I activation, 
likely through a mechanism involving a direct molecular interaction with IRF7. Next, we tes-
ted the physiological impact of IRF7 and RAIDD association. Hence, we expressed IRF7 in the 
RAIDD deficient cells and examined IFN-I activation through luciferase expression driven by 
IFN4α promoters. Consistent with the molecular interaction, IRF7 mediated IFN-I activation 
was significantly reduced in the RAIDD deficient cells when compared to scrRNA control 
(Fig. 3C). Notably, IRF7 mediated IFN production is diminished in RAIDD deficient cells but 
not completely abrogated (Fig. 3C), indicating a RAIDD independent activation of IRF7. Mo-
reover, RAIDD was dispensable for IRF3 mediated IFN-I activation (Fig. 3D). Together, these 
data suggest that RAIDD interacts with IRF7 to promote IFN-I transcription.
RAIDD triggers IKKε but not TBK1 mediated IFN-4α activation
We further investigated the mechanism by which RAIDD affects IRF7 activation. Due to 
defects noticed in nuclear translocation of IRF7 in RAIDD deficient cells (Fig. 1C) we hypo-
thesized that RAIDD may connect IRF7 to its phosphorylating kinases TBK1 or IKKε [16]. Ac-
cordingly, we expressed TBK1 or IKKε in RAIDD competent cells. Strikingly, when compared 
to scramble controls, we found reduced IKKε driven IFN-I promoter activation in cells with 
RAIDD deficiency (Fig. 4A), whereas this was not the case for TBK1 (Fig. 4B). The increasing 
Fig. 3. RAIDD interacts with 
IRF7 and synergizes with IRF7 in 
IFN-I activation. (A, B) 293t cells 
were transfected with RAIDD-
HA, IRF7-YFP, or EGFP control 
plasmids. Whole cell lysates were 
blotted directly after immunopre-
cipitation for RAIDD-HA using an 
anti-HA antibody (A), or immuno-
precipitation for IRF7-YFP using 
an anti-YFP antibody (B). Blotting 
was performed using anti-RAIDD, 
anti-IRF7, anti-TRAF6, anti-IRF3, 
anti-ΙκΒα or GAPDH antibodies 
as indicated (one representative of 
n=3 experiments shown) (Error 
bars indicate SEM). (C, D) 293t 
cells stably expressing scrRNA con-
trol or shRNA RAIDD were tran-
siently transfected with IRF7 (One 
representative of n = 3 is shown) 
(C) or IRF3 (n = 6 is shown) (D) to-
gether with IFN4α luciferase pro-
moter and Renilla plasmids. Dual 
luciferase activity was measured at 
24 h post transfection.
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concentration of RAIDD with TBK1 also failed to enhance the basal induction of IFN-4α luci-
ferase (Fig. 4C). These data indicate, that IKKε but not TBK1 is able to mediate transcriptio-
nal activation of IFN4α and that IKKε  requires RAIDD to mediate its effects.
Full-Length RAIDD drives activation of IFN-I mediated by IKKε and IRF7
To investigate which domains of RAIDD trigger IKKε mediated IFN-I activation, we ge-
nerated deletion constructs of RAIDD, lacking the DD or the CARD (Fig. 5A). We observed 
Fig. 4. RAIDD triggers IKKε mediated IFN4α activation but not the TBK1. (A, B) 293t cells stably expressing 
scrRNA or shRNA of RAIDD were transiently transfected with IKKε (10 ng/ul) or TBK1 (30 ng/ul). together with 
the indicated luciferase promoter and measured for IFN4α luciferase activity 24 h post transfection. (A) (One re-
presentative of n = 3 is shown) and (B) (n = 6 is shown). (C) 293t cells were transiently transfected with increasing 
concentration of RAIDD together with same molecules of TBK1 (30 ng/µl). IFN4α luciferase activities were mea-
sured at 24 h post transfection (n = 6 is shown).
Fig. 5. Full length RAIDD enhances IKKε 
mediated IFN-I activation. (A) A diagram 
illustrating the constructs of RAIDD, Death 
domain truncated RAIDD (∆D), and CARD 
Domain truncated RAIDD (∆C) is shown. 
(B-D) 293t cells were transfected with Emp-
ty Vector (EV), RAIDD (∆C), RAIDD (∆D), 
and Full length RAIDD along with TBK1 (n 
= 6 is shown) (B) and IKKε (n = 6 is shown) 
(C, D). At 24h after transfection, IFN4α 
(Β,Χ) and IFNβ (D) luciferase activities were 
measured.
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that full-length RAIDD significantly increased  IFN-I activation, while neither the CARD nor 
the DD alone promoted IFN-I transcription (Fig. 5B and C). Notably, co-expression of either the  DD or the CARD reduced the effects of full-length RAIDD in this setting, indicating that 
both domains are indeed needed to exert its effects on IFN-I activation (Fig. 5B and C). In 
support of the previous finding, the different forms of RAIDD have no significant impact on 
TBK1 mediated IFN-I activation (Fig. 5D).
To further investigate the molecular interaction of RAIDD, we co-expressed IKKε to-
gether with empty vectors or CARD or DD or full-length RAIDD and examined for the pro-
tein-protein interaction. Although the various mutants of RAIDD were uniformly expressed, 
only the full-length RAIDD showed interaction with IKKε (Fig. 6A). Consistently, the recipro-
cal immunoprecipitation also showed interaction of IKKε only with full length RAIDD but not 
with the mutants (Fig. 6B). Next, we examined the synergetic effects of these components 
and co-expressed empty vectors or CARD or DD or full length RAIDD together with IKKε 
+ IRF7 following analysis of luciferase activity driven by IFN4α and IFNβ promoters. We 
observed significant IFN-I activation only in the presence of the full length RAIDD in sharp 
contrast to both deletion mutants (Fig. 6C and D). We therefore hypothesized that intact 
RAIDD triggered IKKε and IRF7 mediated induction of IFN-I. Taken together, our data shows 
that RAIDD interacts with IRF7 and IKKε to coordinate IKKε mediated IRF7 activation and 
IFN-I production.
Discussion
In this study we have identified RAIDD as a critical regulator of TLR3 driven IFN-I pro-
moter activation, by mediating the interaction between IKKε and IRF7. In cells deficient for 
RAIDD, IFN4α and IFNβ activation was reduced following immune stimulation. RAIDD con-
sist of two functional domains, the RAIDD-DD domain is reported to be essential for the 
PIDD interaction [24, 35] and the RAIDD-CARD domain is essential for the binding with cas-
pase 2 [25, 36]. However, later findings argue against this type of interaction [37, 38]. Our 
data identifies that intact RAIDD is important for PRR driven IFN-I activation.
Pathogens and commensal driven PRR activation results in gradual translocation of 
transcription factors, such as IRF3, IRF7 and NF-κB into the nucleus [39]. Deficiency of IRF7 
in hematopoietic cells results in limited IFN-I production and fatal viral infection [18, 40]. 
Consistently, mutations in human IRF7 coincide with severe influenza infection and limited 
Fig. 6. Full length RAIDD interacts 
with RAIDD and drives the IFN-I 
mediated by IKKε and IRF7. (A) 293t 
cells were lysed followed by immuno-
precipitation (IP) using anti-FLAG 
(RAIDD) (A) or anti-HA (IKKε) (B) 
antibodies. Immunoblots were pro-
bed using anti-FLAG or anti-HA an-
tibodies, along with anti-GAPDH as 
control (one representative of 3 expe-
riments is shown). (C, D) 293t cells 
were transfected with Empty Vector 
(EV), RAIDD (ΔC), RAIDD (ΔD), and 
Full length RAIDD along with IKKε 
and IRF7. After 24h, cells were lysed 
and analyzed for IFN4α (Χ) (n=6 is 
shown) and IFNβ (D) (n = 6 is shown) 
luciferase activities.
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IFN-I expression [41]. The rheostats of IFN-I effects during viral infection remain to be fully 
elucidated. While IFN-I is important for limiting viral replication [42], a growing number of 
other effects have also been identified [31, 32, 39].
IRF7 phosphorylation is regulated by the recently identified factor Pellino3 through the 
interaction with TRAF6 [32]. However, since we did not observe binding of RAIDD to TRAF6, 
we speculate that RAIDD triggers activation and nuclear translocation of IRF7 through a Pel-
lino3 independent mechanism. Moreover, the 2´-5´-oligoadenylate synthetase (OAS) family 
member OASL1 has been shown to prevent IRF7 mRNA translation and consequently IFN-I 
production [31]. Although we also observed reduced IRF7 expression after stimulation of 
cells expressing shRNAs targeting RAIDD, the molecular interaction as well as the impaired 
nuclear translocation of IRF7 in shRNA RAIDD expressing cells suggests an interaction of 
RAIDD and IRF7 at the protein level. Notably, the transcription factor ELF4 can enhance IRF3 
and IRF7 binding following phosphorylation by TBK1 [43]. However, we did not observe a 
difference in TBK1 mediated IFN-4α promoter activity following knockdown of RAIDD. Our 
data identifies an alternative mechanism in which RAIDD connects IRF7 to the upstream 
kinase ΙΚΚε, thereby increasing IFN-I activity.
In conclusion, we identified RAIDD as a crucial adaptor protein for innate immune acti-
vation. We have delineated an unexpected TBK1-independent signaling pathway that feeds 
via IKKε to IRF7 activation. Consequently our data shows that this pathway is crucial for 
IFN-I production.
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